Physician profile
Lawrence Weil
NPI 1073517678
$9,419.46
in general payments reported to CMS, 2019-2025
50 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 84% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $255 · 2021: $1,081 · 2022: $1,288 · 2023: $1,138 · 2024: $1,290 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,683 · Travel and Lodging: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.49 |
| Travel and Lodging | $1,445.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $1,356.17 | 2025 | Sprint Pns System |
| Abbvie INC. | $970.24 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Stryker Corporation | $790.43 | 2024-2025 | Mild Device Kit |
| Electronic Waveform Lab, INC. | $559.05 | 2019-2025 | |
| Nevro Corp. | $470.01 | 2019-2024 | Senza |
| Pfizer INC. | $444.29 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.06 | 2019-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $424.60 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $378.32 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $360.61 | 2019-2024 | Belbuca |
| Biohaven Pharmaceutical Holding Company Ltd. | $358.19 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $297.97 | 2024-2025 | |
| Redhill Biopharma INC. | $214.36 | 2021-2022 | |
| Forte Bio-Pharma LLC | $194.48 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Boston Scientific Corporation | $192.73 | 2020-2024 | Wavewriter Alpha Prime 16 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $171.65 | 2019 | |
| Scilex Pharmaceuticals INC. | $149.19 | 2021-2024 | Ztlido |
| Saluda Medical Americas, INC. | $127.15 | 2024-2025 | Evoke |
| Astrazeneca Pharmaceuticals Lp | $124.95 | 2019 | |
| Orexo US, INC. | $117.71 | 2019 | |
| Abbott Laboratories | $94.35 | 2023-2024 | Proclaim, Eterna |
| Averitas Pharma INC. | $90.46 | 2024 | Qutenza |
| Horizon Therapeutics Plc | $90.44 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $83.14 | 2019-2022 | |
| Almatica Pharma LLC | $67.59 | 2021-2023 | Gralise |
| Grt US Holding, INC. | $62.28 | 2022 | |
| Allergan, INC. | $61.65 | 2019-2021 | |
| Si-Bone, INC. | $60.36 | 2019-2024 | |
| Curonix LLC | $54.89 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ibsa Pharma INC. | $50.83 | 2021-2023 | Tirosint, Licart |
| Nalu Medical, INC. | $49.49 | 2022-2024 | Nalu Neurostimulation System |
| Arbor Pharmaceuticals, INC. | $47.95 | 2019-2021 | |
| Daiichi Sankyo INC. | $45.91 | 2019 | |
| Relievant Medsystems, INC. | $43.52 | 2023 | Intracept |
| Bioventus LLC | $39.69 | 2021 | |
| Mdd US Operations, LLC | $38.84 | 2019-2020 | |
| Medtronic, INC. | $36.38 | 2023 | Intellis Adaptivestim |
| Vertos Medical, INC. | $32.97 | 2022-2024 | Mild Device Kit |
| Hikma Pharmaceuticals USA | $25.45 | 2021-2022 | |
| Convatec INC. | $24.85 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.91 | 2019 | |
| Vertiflex, INC. | $20.79 | 2019 | |
| Gilead Sciences, INC. | $19.61 | 2019 | |
| Fidia Pharma USA INC. | $19.39 | 2022 | |
| Indivior INC. | $17.92 | 2024 | Sublocade |
| Ferring Pharmaceuticals INC. | $17.79 | 2022 | |
| Lilly USA, LLC | $17.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.56 | 2019 | |
| Zyla Life Sciences, INC. | $14.28 | 2020 | |
| Medline Industries Lp | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Weil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.